Ocrelizumab appears to reduce relapse and disability in multiple sclerosis but quality of evidence is moderate

Graziella Filippini

Research output: Contribution to journalComment/debate

Original languageEnglish
Pages (from-to)215-216
Number of pages2
JournalEvidence-Based Medicine
Volume22
Issue number6
DOIs
Publication statusPublished - Dec 1 2017

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ocrelizumab appears to reduce relapse and disability in multiple sclerosis but quality of evidence is moderate. / Filippini, Graziella.

In: Evidence-Based Medicine, Vol. 22, No. 6, 01.12.2017, p. 215-216.

Research output: Contribution to journalComment/debate

@article{cf3d1198520e44d6903b61238e5dce26,
title = "Ocrelizumab appears to reduce relapse and disability in multiple sclerosis but quality of evidence is moderate",
author = "Graziella Filippini",
year = "2017",
month = "12",
day = "1",
doi = "10.1136/ebmed-2017-110721",
language = "English",
volume = "22",
pages = "215--216",
journal = "Evidence-Based Medicine",
issn = "1356-5524",
publisher = "BMJ Publishing Group",
number = "6",

}

TY - JOUR

T1 - Ocrelizumab appears to reduce relapse and disability in multiple sclerosis but quality of evidence is moderate

AU - Filippini, Graziella

PY - 2017/12/1

Y1 - 2017/12/1

UR - http://www.scopus.com/inward/record.url?scp=85037168907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037168907&partnerID=8YFLogxK

U2 - 10.1136/ebmed-2017-110721

DO - 10.1136/ebmed-2017-110721

M3 - Comment/debate

AN - SCOPUS:85037168907

VL - 22

SP - 215

EP - 216

JO - Evidence-Based Medicine

JF - Evidence-Based Medicine

SN - 1356-5524

IS - 6

ER -